Wave Life Sciences Ltd.

Wave Life Sciences Ltd. completed its redomiciliation, making Wave Life Sciences, Inc., a Delaware corporation, the new ultimate parent company. All ordinary shares of the Singapore entity were exchanged on a one-for-one basis for common stock of the Delaware entity. The Singapore entity's shares will be delisted from Nasdaq, and the Delaware entity's common stock will begin trading under the same 'WVE' symbol on August 10, 2026. The company also entered into indemnification agreements with its directors and executive officers and assumed the 2014 Equity Incentive Plan.

Wave Life Sciences Ltd. announced that its management team, led by President and CEO Paul Bolno, MD, MBA, is scheduled to participate in two upcoming investor conferences in August 2026. Dr. Bolno will engage in analyst-led fireside chats at the BofA Securities 2026 SMID Cap Executive Insights Event on August 11 and the Canaccord Genuity 46th Annual Growth Conference on August 12. Live webcasts and replays of these presentations will be accessible via the company's investor relations website.

Wave Life Sciences Ltd. reported a net loss of $69.36 million for the second quarter of 2026, with revenue at $2.27 million. For the first six months of 2026, the company's net loss slightly decreased to $95.44 million, while revenue significantly increased to $40.52 million. The company also announced that its redomiciliation to Delaware was approved by shareholders and the High Court of Singapore, expected to take effect in August 2026, and extended its manufacturing facility lease.

Wave Life Sciences Ltd. reported its second quarter 2026 financial results, with cash, cash equivalents, and marketable securities of $490.6 million as of June 30, 2026, providing a cash runway into Q3 2028. The company posted a net loss of $69.4 million on revenues of $2.3 million for the quarter. Alongside the financial update, Wave Life Sciences provided significant business updates, including the initiation of dosing in the Phase 2a INLIGHT trial for WVE-007 in obesity and a scheduled FDA meeting for WVE-006's potential accelerated approval pathway.

Wave Life Sciences reported its second-quarter 2026 financial results and provided a business update, highlighting significant progress in its clinical pipeline. Dosing has begun in the Phase 2a multidose portion of the INLIGHT trial for WVE-007 in obesity, with Phase 2 combination trials expected to start in 2H 2026. The company has an FDA meeting scheduled for late summer 2026 to discuss an accelerated approval pathway for WVE-006 for AATD, supported by RestorAATion-2 data. Wave also reported $490.6 million in cash, cash equivalents, and marketable securities as of June 30, 2026, providing a cash runway into Q3 2028, despite increased net losses.

Wave Life Sciences Ltd. announced that it has obtained the necessary shareholder approval for its proposed redomiciliation to the United States. The company has filed an application with the High Court of the Republic of Singapore to approve the scheme of arrangement, with a hearing scheduled for July 14, 2026. The redomiciliation remains subject to this court approval.

Wave Life Sciences announced the initiation of the Phase 2a multidose portion of its INLIGHT trial for WVE-007, an investigational GalNAc-siRNA for obesity. This portion will evaluate WVE-007 as a monotherapy in individuals with high BMI and comorbidities. The company also reported positive six-month follow-up data from the Phase 1 single-dose portion, showing clinically meaningful reductions in visceral fat (-14%), total fat (-5%), and waist circumference (-3%) with a single 240 mg dose, supporting once or twice-yearly dosing. Wave plans to initiate additional Phase 2 trials for WVE-007 in 2H 2026.

Wave Life Sciences announced that its management team is scheduled to participate in two upcoming investor conferences in June 2026. Paul Bolno, MD, MBA, President and CEO, will engage in analyst-led fireside chats at both the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. Live webcasts of these presentations will be accessible via the "Investor Events" section of the company's website, with replays available for a limited time.

Wave Life Sciences announced positive updated data from its RestorAATion-2 trial for WVE-006, an investigational RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD). The trial demonstrated WVE-006's ability to achieve an MZ-like phenotype, generating 64% wild-type M-AAT and reducing harmful Z-AAT by 71% in the 200 mg biweekly cohort, with sustained effects for at least three months. The therapy also restored dynamic AAT production and maintained a favorable safety profile, positioning it as a potential new standard of care for both lung and liver manifestations of AATD.

Wave Life Sciences announced updated positive data from its RestorAATion-2 trial of WVE-006 for alpha-1 antitrypsin deficiency (AATD). The data showed WVE-006's potential to address both lung and liver manifestations, with significant reductions in harmful Z-AAT and restoration of healthy M-AAT, consistent with monthly dosing. The therapy also demonstrated dynamic AAT production during acute phase responses and a favorable safety profile. The company expects FDA feedback on a potential accelerated approval pathway by mid-2026.